MX2021014782A - Formulaciones de levodopa para el alivio rapido de la enfermedad de parkinson. - Google Patents

Formulaciones de levodopa para el alivio rapido de la enfermedad de parkinson.

Info

Publication number
MX2021014782A
MX2021014782A MX2021014782A MX2021014782A MX2021014782A MX 2021014782 A MX2021014782 A MX 2021014782A MX 2021014782 A MX2021014782 A MX 2021014782A MX 2021014782 A MX2021014782 A MX 2021014782A MX 2021014782 A MX2021014782 A MX 2021014782A
Authority
MX
Mexico
Prior art keywords
levodopa
patient
inhalation
plasma
parkinson
Prior art date
Application number
MX2021014782A
Other languages
English (en)
Inventor
Martin Freed
Richard Batycky
LIPP Michael M
Original Assignee
Civitas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Civitas Therapeutics Inc filed Critical Civitas Therapeutics Inc
Publication of MX2021014782A publication Critical patent/MX2021014782A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Abstract

La presente invención proporciona métodos para proporcionar rápido alivio de fluctuaciones motores en un paciente con enfermedad de Parkinson. Los métodos de la invención comprenden administración pulmonar de la levodopa mediante inhalación en concentraciones terapéuticamente eficaces de tal manera la concentración de la levodopa del plasma del paciente aumenta por al menos 200 ng/ml dentro de los 10 minutos o menos después de la inhalación tal como se comparó con la concentración de la levodopa en el plasma del paciente previo a la inhalación de la levodopa y en donde la concentración de plasma del paciente permanece aumentada por al menos aproximadamente 200 ng/ml por un período de al menos 15 minutos después de la inhalación. Los métodos de la invención son específicamente útiles para el tratamiento de fluctuaciones motoras que surgen como resultado de los niveles de plasma de levodopa mal controlados en un paciente.
MX2021014782A 2012-10-22 2013-10-21 Formulaciones de levodopa para el alivio rapido de la enfermedad de parkinson. MX2021014782A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261716740P 2012-10-22 2012-10-22
US201361813605P 2013-04-18 2013-04-18
US201361813725P 2013-04-19 2013-04-19
PCT/US2013/065838 WO2014066208A1 (en) 2012-10-22 2013-10-21 Levodopa formulations for rapid relief of parkinson's disease

Publications (1)

Publication Number Publication Date
MX2021014782A true MX2021014782A (es) 2023-03-23

Family

ID=50545142

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015005038A MX2015005038A (es) 2012-10-22 2013-10-21 Formulaciones de levodopa para el alivio rapido de la enfermedad de parkinson.
MX2021014782A MX2021014782A (es) 2012-10-22 2013-10-21 Formulaciones de levodopa para el alivio rapido de la enfermedad de parkinson.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015005038A MX2015005038A (es) 2012-10-22 2013-10-21 Formulaciones de levodopa para el alivio rapido de la enfermedad de parkinson.

Country Status (18)

Country Link
US (1) US20150328175A1 (es)
EP (2) EP2908805B1 (es)
JP (2) JP2016500690A (es)
KR (2) KR20150102960A (es)
CN (2) CN110812350A (es)
AU (3) AU2013334949B2 (es)
BR (1) BR112015009088A2 (es)
CA (1) CA2888994C (es)
DK (1) DK2908805T3 (es)
ES (1) ES2886529T3 (es)
HK (2) HK1212258A1 (es)
MX (2) MX2015005038A (es)
NZ (1) NZ708414A (es)
PL (1) PL2908805T3 (es)
PT (1) PT2908805T (es)
RU (2) RU2685718C2 (es)
SG (2) SG10201804985QA (es)
WO (1) WO2014066208A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ708415A (en) * 2012-10-22 2018-11-30 Civitas Therapeutics Inc Reducing inter-patient variability of levodopa plasma concentrations
BR112015010601B1 (pt) 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
US20170296498A1 (en) * 2014-04-21 2017-10-19 Civitas Therapeutics, Inc. Rapid Relief of Motor Fluctuations in Parkinson's Disease
KR20200118033A (ko) * 2018-01-05 2020-10-14 임펠 뉴로파마 인코포레이티드 정밀 후각기관 장치에 의한 레보도파 분말의 비강내 전달
US11517548B2 (en) 2018-07-19 2022-12-06 Impel Pharmaceuticals Inc. Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
GB0027020D0 (en) * 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
EP1531798B1 (en) * 2002-03-20 2012-06-06 Civitas Therapeutics, Inc. Pulmonary delivery for levodopa
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
GB2454480A (en) * 2007-11-07 2009-05-13 Vectura Group Plc Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders

Also Published As

Publication number Publication date
AU2013334949A1 (en) 2015-06-11
AU2013334949B2 (en) 2018-08-09
EP2908805A1 (en) 2015-08-26
RU2015119377A (ru) 2016-12-10
AU2018253538A1 (en) 2018-11-22
PL2908805T3 (pl) 2021-12-27
NZ708414A (en) 2018-11-30
HK1212623A1 (zh) 2016-06-17
WO2014066208A1 (en) 2014-05-01
RU2019111096A (ru) 2020-10-12
KR20210075224A (ko) 2021-06-22
AU2020250325A1 (en) 2020-11-12
CN110812350A (zh) 2020-02-21
EP2908805A4 (en) 2016-07-06
EP2908805B1 (en) 2021-06-09
ES2886529T3 (es) 2021-12-20
MX2015005038A (es) 2015-12-01
SG11201503129RA (en) 2015-05-28
CN104884046A (zh) 2015-09-02
KR20150102960A (ko) 2015-09-09
DK2908805T3 (da) 2021-09-13
US20150328175A1 (en) 2015-11-19
PT2908805T (pt) 2021-09-10
JP2018150339A (ja) 2018-09-27
HK1212258A1 (en) 2016-06-10
EP3943080A1 (en) 2022-01-26
BR112015009088A2 (pt) 2017-07-04
CA2888994A1 (en) 2014-05-01
JP2016500690A (ja) 2016-01-14
CA2888994C (en) 2022-10-04
RU2685718C2 (ru) 2019-04-23
SG10201804985QA (en) 2018-07-30
AU2018253538B2 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
AU2018253538A1 (en) Levodopa formulations for rapid relief of parkinson's disease
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
MX2022004103A (es) Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2016009427A (es) Formulaciones de pridopidina de liberacion modificada.
PH12015500407A1 (en) Methods of treating hypertriglyceridemia
IN2015DN00376A (es)
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
MX2015006120A (es) Compuestos novedosos oralmente biodisponibles que modulan el control de la respiracion, y metodos de uso de los mismos.
NZ702730A (en) Treatment of motor and movement disorder side effects associated with parkinson’s disease treatments
WO2012170918A3 (en) Methods of treatment for retinal diseases
WO2014184576A3 (en) Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain
MX2018006247A (es) Metodos para tratar la enfermedad de alzheimer y trastornos relacionados.
IN2015DN04151A (es)
MX350195B (es) Analogos de cistamina para el tratamiento de la enfermedad de parkinson.
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
AU2018253542A1 (en) Reducing inter-patient variability of levodopa plasma concentrations
MX2015013137A (es) Compuestos novedosos de modulación del control de la respiración, y sus métodos de uso.
UA112981C2 (uk) Варіант людського gdnf
WO2013181217A3 (en) Novel compounds and compositions for treatment of breathing control disorders or diseases
MX2020001217A (es) Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.
MX2015008676A (es) Formulaciones de nanoparticulas de metadichol, liquidas y en gel.
BR112015002384A2 (pt) combinações farmacêuticas compreendendo um inibidor de b-raf, um inibidor de egfr e opcionalmente um inibidor de pi3k-alfa
EA201201226A1 (ru) Твердая лекарственная форма, обладающая анорексигенным действием (варианты)